| 000 | 01213 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250518011029.0 | ||
| 264 | 0 | _c20190620 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1532-1924 | ||
| 024 | 7 |
_a10.1016/j.beha.2018.09.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRowe, Jacob M | |
| 245 | 0 | 0 |
_aProgress and predictions: AML in 2018. _h[electronic resource] |
| 260 |
_bBest practice & research. Clinical haematology _c12 2018 |
||
| 300 |
_a337-340 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 | _aHigh-Throughput Nucleotide Sequencing |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsocitrate Dehydrogenase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm, Residual |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 650 | 0 | 4 |
_afms-Like Tyrosine Kinase 3 _xantagonists & inhibitors |
| 773 | 0 |
_tBest practice & research. Clinical haematology _gvol. 31 _gno. 4 _gp. 337-340 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.beha.2018.09.002 _zAvailable from publisher's website |
| 999 |
_c29081265 _d29081265 |
||